

Light-Triggered Myosin Activation for Probing Dynamic Cellular Processes**

Brenda N. Goguen, Brenton D. Hoffman, James R. Sellers, Martin A. Schwartz, and Barbara Imperiali*

Myosin II is an ATPase motor protein essential for many cellular functions including cell migration^[1] and division.^[2] In nonmuscle cells, myosin modulates protrusions at the leading edge and promotes retraction at the trailing edge during migration,^[3] while during cytokinesis, myosin is required for contraction of the cleavage furrow.^[4] For nonmuscle myosin, these varied functions are regulated by phosphorylation of the associated myosin regulatory light chain (mRLC) protein at Ser19, which activates the myosin complex to promote myosin assembly, cell contractility, and stress fiber formation.^[5] Upon phosphorylation of the mRLC at both Thr18 and Ser19, these activities are further enhanced.^[6] The dramatic effects of phosphorylation can also be recapitulated *in vitro*. Specifically, myosin and the proteolytic derivative heavy meromyosin (HMM),^[7] which contains only one-third of the C-terminal myosin tail, exhibit low *in vitro* activities when associated with the nonphosphorylated mRLC. Phosphorylation of Ser19 amplifies actin-activated ATPase activities 10 – 1000-fold^[8] and leads to myosin-mediated actin translocation.^[9]

While myosin has been studied extensively for almost five decades, questions surrounding the dynamic interactions of the protein within live cells remain. Methods currently used to study myosin and modulate activity include gene deletions or siRNA-mediated knockdown of gene expression,^[3] overexpression of kinases that phosphorylate the mRLC,^[10] and small molecule inhibitors of myosin,^[11] mRLC kinases,^[12] and myosin phosphatase.^[13] While these methods have provided a wealth of valuable information about myosin, they do not enable studies of the spatial dynamics of myosin regulation because localized activation cannot be achieved. Additionally, genetic approaches provide imprecise temporal control over protein function, preventing real-

time studies of the protein. Thus, we sought to develop chemical tools to overcome these drawbacks and to complement the existing approaches by enabling direct and controlled myosin activation through the semisynthesis of a photoactivated mRLC. The light-mediated activation is achieved by the incorporation of a photolabile protecting group, or “caging group,” onto the essential phosphate of pSer19 within the full-length mRLC. The caging group masks the phosphate functionality and renders the protein biologically inactive until irradiation removes the masking group and releases the active native phosphoprotein. By using light as the trigger for phosphorylation, this strategy offers a kinase-independent method to activate myosin with precise spatial and temporal resolution and enables researchers to obtain real-time information about the downstream effects of myosin phosphorylation within a complex network of interactions.^[14]

The 1-(2-nitrophenyl)ethyl (NPE) caging group has been employed for cellular applications because it is efficiently released, under biologically-compatible conditions, at 365 nm. Peptides and proteins containing NPE-caged phosphorylated amino acids have been successfully exploited for the study of many diverse systems.^[15] Additionally, a general method for incorporating NPE-caged thiophosphoamino acids, which, upon irradiation, function similarly to the corresponding phosphorylated species but with greater resistance to phosphatases, has been reported^[16] and can be used for advancing studies of myosin.


Herein we report the development of a chemical approach to investigate myosin function through the preparation of unnatural amino acid mutants of the mRLC. We present an efficient semisynthesis of full-length mRLC through expressed protein ligation for the site-specific incorporation of phosphorylation at Ser19 (pSer19) and Thr18 (pThr18) and the genesis of caged phosphoserine (cpSer) and caged thiophosphoserine (c(S)pSer) at position 19. Caging of pSer19 eliminates myosin and HMM activities, and irradiation releases the native phospho-mRLC to restore activity to nearly native phosphorylated levels (Figure 1). Microinjection of myosin exchanged with the caged protein into live cells and subsequent irradiation releases the phosphoprotein within cells. This tool is poised to facilitate future investigations of the downstream effects of myosin activation.

[*] B. N. Goguen, Prof. B. Imperiali
Departments of Chemistry and Biology
Massachusetts Institute of Technology
Cambridge, MA 02139 (USA)
Fax: (+1) 617-452-2799
E-mail: imper@mit.edu
Homepage: <http://web.mit.edu/imperiali>

Dr. B. D. Hoffman, Prof. M. A. Schwartz
Department of Microbiology
University of Virginia
Charlottesville, VA 22908 (USA)

Dr. J. R. Sellers
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD 20892 (USA)

[**] We thank Dr. Andreas Aemissegger for synthesis of the caged amino acids. This research was supported by the NIH Cell Migration Consortium (GM064346). B.N.G. was supported by the NIGMS Biotechnology Training Grant, and B.D.H. was supported by an AHA Fellowship.

 Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.






Figure 1. Installation of NPE-caged pSer19 into the mRLC is achieved by expressed protein ligation. The caging group masks the phosphate necessary for myosin activation until irradiation releases it to generate the native phosphoprotein and restore activity. Image was modified from Protein Data Bank file 1WDC.

Semisynthesis of the mRLC was achieved through native chemical ligation (NCL)^[17] between a synthetic peptide thioester corresponding to the N-terminal region of the mRLC (residues 1 – 23) and a recombinant protein fragment comprising the remaining C-terminal residues (residues 25 – 171) and a Met24Cys mutation (Scheme 1). To probe the effects of phosphorylation at discrete sites of the mRLC, the protein was synthesized with no phosphorylation (**1**) and with pSer19 (**2**), pThr18 (**3**), pThr18 pSer19 (**4**), cpSer19 (**5**), and c(S)pSer19 (**6**).



Scheme 1. Semisynthesis of the full-length mRLC. The C-terminal portion of the mRLC is expressed heterologously in *E. coli*. TEV proteolysis releases GST and reveals the N-terminal cysteine, which reacts in the NCL with the synthetic peptide thioester to generate the full-length mRLC.

Table 1. Peptide thioester derivatives used in the semisynthesis of mRLC.^[a]



FLAG-mRLC(1-23): DYKDDDDK-SSKAKTKTTKKRPQRA **XY** NVFA

Entry	Derivative	R ¹	R ²
1	NonP	OH	OH
2	pSer19	OH	OPO ₃ ²⁻
3	pThr18	OPO ₃ ²⁻	OH
4	pThr18 pSer19	OPO ₃ ²⁻	OPO ₃ ²⁻
5	cpSer19	OH	
6	c(S)pSer19	OH	

[a] Peptides were synthesized by Fmoc-based solid phase peptide synthesis as C-terminal thioesters.

The peptide thioesters containing the phosphorylated or caged phosphorylated derivatives were synthesized through Fmoc-based solid phase peptide synthesis (Tables 1, S1). The C-terminal portion of the protein was expressed in *E. coli* as a fusion to glutathione S-transferase (GST) to enhance expression and aid purification. Next, tobacco etch virus (TEV) proteolysis released GST to expose the N-terminal cysteine needed for the ligation. The peptide and protein

fragments were combined in the NCL reaction, which efficiently afforded milligram quantities of the full-length mRLC at about 75% conversion relative to the unligated protein (Figure S1). N-terminal FLAG epitope and C-terminal hexahistidine tags facilitated isolation of the semisynthetic product from unligated protein and excess peptide, respectively. After purification, the mass of the protein was confirmed by MALDI analysis.

We then characterized the ability of the semisynthetic protein to regulate in vitro myosin activity and to enable myosin photoactivation. Semisynthetic mRLC was exchanged for the native mRLC in chicken gizzard smooth muscle HMM and myosin (Figure S2) and then tested in ATPase^[18] and sliding filament assays.^[19] We first focused on the ATPase assays, and due to greater tractability in solution, HMM, rather than myosin, was used.^[7] Similar to HMM with the native nonphosphorylated mRLC, the actin-activated ATPase activity of HMM exchanged with **1** was negligible (Figure 2a). HMM exchanged with **2** displayed activity similar to that of HMM phosphorylated by myosin light chain kinase (MLCK) (0.80 ± 0.07 and 0.98 ± 0.13 s⁻¹, respectively). These experiments establish that the semisynthetic mRLC fully and faithfully regulates HMM enzymatic activity. Additionally, introduction of the FLAG epitope and hexahistidine tags do not influence function.

In addition to Ser19, the mRLC can also be phosphorylated at Thr18.^[20] Studies of Thr18 phosphorylation alone have relied on a Ser19Ala mutation because Ser19 is normally phosphorylated before Thr18.^[21] Moreover, mRLC diphosphorylation has been observed in vitro and in cells, but complete in vitro phosphorylation requires high concentrations of MLCK.^[20] Our semisynthetic approach provides, for the first time, convenient access to homogeneously phosphorylated proteins, allowing the effects of defined phosphorylation to be examined without the need for mutations at positions 18 or 19 of the mRLC. ATPase assays of HMM exchanged with **3** showed that phosphorylation of Thr18 moderately increases activity to 0.18 ± 0.03 s⁻¹, whereas phosphorylation at both Thr18 and Ser19 (**4**) generates even greater activity (1.16 ± 0.11 s⁻¹) than pSer19 alone (Figure 2a). These trends are consistent with previous studies on the effects of kinase-mediated Thr18 phosphorylation and diphosphorylation.^[21]




Figure 2. Actin-activated ATPase activities of HMM. The values are the means \pm SD of at least three trials. NonP, nonphosphorylated; P, phosphorylated by MLCK. a) Actin-activated ATPase activity of HMM with native (gray bars) and noncaged semisynthetic derivatives (black bars). b) Actin-activated ATPase activity of HMM with semisynthetic noncaged derivatives (black bars) and caged derivatives (open bars) before (-UV) and after (+UV) irradiation at 365 nm for 90 s.

Next, we investigated the ability to photoactivate the protein. We first used RP-HPLC analysis to examine the kinetics of NPE removal after irradiation of the caged peptide on a DNA transilluminator (365 nm) (Figure S3). The duration of uncaging was optimized according to this analysis, which demonstrated that

irradiation for 90 s released about 70% of the free phosphopeptide. Western blot analysis of the full-length caged proteins (**5** and **6**) with an anti-pSer19 mRLC antibody confirmed that the phospho- and thiophosphoproteins were generated upon irradiation (Figure S4).

Following exchange of caged mRLCs **5** and **6** into HMM, actin-activated ATPase assays demonstrated that the activity of the caged proteins was low and mimicked that of nonphosphorylated mRLC **1** (Figure 2b). Irradiation on a transilluminator at 365 nm for 90 s increased activity about 20-fold to levels near that of HMM exchanged with the semisynthetic pSer19 mRLC (**2**). Importantly, the caged proteins completely suppress HMM ATPase activity, indicating that the caging group is sufficient to maintain the inhibited state of the protein. The activities following uncaging (0.48 ± 0.04 and 0.43 ± 0.05 s^{-1} for **5** and **6**, respectively) are consistent with restoration of about 60% activity compared to that of HMM with semisynthetic pSer19 mRLC **2** and lie within the range expected based on the HPLC peptide uncaging analysis. Thus, irradiation enables direct control over the release of the phosphorylated mRLC and, correspondingly, over HMM activation.




Figure 3. In vitro myosin sliding filament assays. a) The mean velocities \pm SD of at least 45 actin filaments during incubation with native myosin (gray bars) and myosin exchanged with the noncaged semisynthetic (black bars) and caged semisynthetic (open bars) mRLCs. NMO, no motility observed; NonP, nonphosphorylated; P, phosphorylated by MLCK. b) Actin filament paths from a representative field before (-UV) and after (+UV) 90 s irradiation of myosin exchanged with cpSer19 mRLC **5**.

To further characterize the semisynthetic proteins and the caging system, we performed sliding filament assays, which assess the force-generating ability of myosin. In this assay, we measure the velocities of fluorescently-labeled actin filaments propelled by myosin bound to a nitrocellulose-coated glass coverslip. Myosin was used in these assays because it produced more consistent filament movement than HMM. Nonphosphorylated myosin and myosin exchanged with **1** did not move the actin filaments, but both MLCK-phosphorylated myosin and myosin exchanged with **2** led to significant movement with velocities around $0.9 \mu m s^{-1}$ (Figure 3a). Each phosphorylated semisynthetic derivative generated filament movement at velocities between 0.7 and $1.0 \mu m s^{-1}$. A one-way ANOVA followed by Tukey's post-hoc test indicated that the

differences among myosin exchanged with **2**, **3**, and **4** are statistically significant, with all comparisons yielding $p < 0.0001$ (Figure 3a). The velocities follow the relative trends observed in the ATPase assays with pThr18 producing the smallest and pThr18 pSer19 generating the greatest velocities. These results are consistent with a previous study in which myosin with an mRLC phosphorylated at Thr18 and containing a Ser19Ala mutation generated slightly lower filament velocities than the pSer19 and pThr18 pSer19 derivatives.^[21b] However, our results also indicate differences between phosphorylation at Ser19 and double phosphorylation (pThr18 pSer19), which have not been previously reported.

With both caged proteins **5** and **6**, negligible filament movement was observed before irradiation (Figures 3a, 3b, S5). In contrast, irradiation of myosin prior to the assay generated significant filament movement with velocities comparable to those observed with MLCK-phosphorylated myosin or myosin exchanged with the semisynthetic pSer19 mRLC. Although about 60% of the HMM ATPase activity was achieved after uncaging, the sliding filament velocities were fully restored following irradiation. Previous studies have shown that while steady-state ATPase activities increase proportionally with the degree of myosin phosphorylation,^[22] sliding filament velocities follow a nonlinear trend and reach a maximal value even in the presence of nonphosphorylated myosin.^[23]

The in vitro studies establish that caging of pSer19 provides effective photochemical control over myosin activity. Finally, in order to test these chemical tools in live cells, we microinjected the caged mRLC into COS7 cells and investigated uncaging in situ. Initially, the caged thiophosphorylated mRLC **6** was used to minimize potential complicating effects from cellular phosphatases. Additionally, because incorporation of the injected mRLC into endogenous myosin complexes was slow, gizzard smooth muscle myosin exchanged with the caged protein was prepared in vitro and microinjected. Following irradiation of the injected cells on a transilluminator, the cells were fixed, stained with an anti-pSer19 mRLC antibody, and analyzed by immunofluorescence microscopy. The signal from the anti-pSer19 mRLC antibody was significantly higher following uncaging compared to injected cells that had not been irradiated (Figures 4, S6). These studies indicate that the thiophosphorylated protein can be readily and reproducibly generated within a cellular system and represent the foundation for future investigations of the real-time effects of myosin phosphorylation within living cells.




Figure 4. Cells injected with myosin exchanged with **6** and Texas Red-labeled dextran marker before (Caged) or after (Uncaged) irradiation. The cells were fixed and stained with an antibody specific for pSer19 mRLC. Scale bar: $10 \mu m$.

In summary, the semisynthetic approach provides convenient access to milligram quantities of various phosphorylated and caged phosphorylated mRLC derivatives, which facilitate studies of

individual sites of phosphorylation. This general method can be readily adapted for the incorporation of other unnatural elements into the N-terminal domain of the mRLC. Additionally, the caged protein enables precise photocontrol over HMM and myosin activity. Uncaging efficiently furnishes the phospho- and thiophosphoproteins that appropriately regulate HMM and myosin activity. The in vitro characterization of the semisynthetic protein and the cellular uncaging experiments provide the basis for subsequent studies of myosin phosphorylation within a cellular environment. For instance, this system could be used to further address effects of myosin phosphorylation on stress fiber and focal adhesion formation. Offering the unique ability to activate myosin with precise spatial and temporal resolution, this approach promises to help unravel the complex role of the protein within the cell.

Received: ((will be filled in by the editorial staff))

Published online on ((will be filled in by the editorial staff))

Keywords: Bioorganic chemistry · Enzymes · Phosphorylation · Protein design · Semisynthesis

- [1] D. A. Lauffenburger, A. F. Horwitz, *Cell* **1996**, *84*, 359.
 [2] A. De Lozanne, J. A. Spudich, *Science* **1987**, *236*, 1086.
 [3] M. Vicente-Manzanares, X. Ma, R. S. Adelstein, A. R. Horwitz, *Nat. Rev. Mol. Cell Biol.* **2009**, *10*, 778.
 [4] S. Komatsu, T. Yano, M. Shibata, R. A. Tuft, M. Ikebe, *J. Biol. Chem.* **2000**, *275*, 34512.
 [5] a) M. Chrzanowska-Wodnicka, K. Burridge, *J. Cell Biol.* **1996**, *133*, 1403; b) T. Watanabe, H. Hosoya, S. Yonemura, *Mol. Biol. Cell* **2007**, *18*, 605.
 [6] S. Komatsu, M. Ikebe, *J. Cell Biol.* **2004**, *165*, 243.
 [7] M. Ikebe, D. J. Hartshorne, *Biochemistry* **1985**, *24*, 2380.
 [8] a) J. R. Sellers, M. D. Pato, R. S. Adelstein, *J. Biol. Chem.* **1981**, *256*, 13137; b) J. R. Sellers, *J. Biol. Chem.* **1985**, *260*, 15815.
 [9] J. L. Tan, S. Ravid, J. A. Spudich, *Annu. Rev. Biochem.* **1992**, *61*, 721.
 [10] a) M. Murata-Hori, Y. Fukuta, K. Ueda, T. Iwasaki, H. Hosoya, *Oncogene* **2001**, *20*, 8175; b) G. Hecht, *et al.*, *Am. J. Physiol.* **1996**, *271*, C1678.
 [11] A. F. Straight, A. Cheung, J. Limouze, I. Chen, N. J. Westwood, J. R. Sellers, T. J. Mitchison, *Science* **2003**, *299*, 1743.
 [12] a) M. Saitoh, T. Ishikawa, S. Matsushima, M. Naka, H. Hidaka, *J. Biol. Chem.* **1987**, *262*, 7796; b) M. Uehata, *et al.*, *Nature* **1997**, *389*, 990.
 [13] L. Chartier, L. L. Rankin, R. E. Allen, Y. Kato, N. Fusetani, H. Karaki, S. Watabe, D. J. Hartshorne, *Cell Motil. Cytoskeleton* **1991**, *18*, 26.
 [14] D. M. Rothman, M. D. Shults, B. Imperiali, *Trends Cell Biol.* **2005**, *15*, 502.
 [15] a) M. E. Vazquez, M. Nitz, J. Stehn, M. B. Yaffe, B. Imperiali, *J. Am. Chem. Soc.* **2003**, *125*, 10150; b) A. Nguyen, D. M. Rothman, J. Stehn, B. Imperiali, M. B. Yaffe, *Nat. Biotechnol.* **2004**, *22*, 993; c) M. E. Hahn, T. W. Muir, *Angew. Chem.* **2004**, *116*, 5924; *Angew. Chem. Int. Ed. Engl.* **2004**, *43*, 5800; d) D. Humphrey, Z. Rajfur, M. E. Vazquez, D. Scheswohl, M. D. Schaller, K. Jacobson, B. Imperiali, *J. Biol. Chem.* **2005**, *280*, 22091; e) E. M. Vogel, B. Imperiali, *Protein Sci.* **2007**, *16*, 550.
 [16] A. Aemissegger, C. N. Carrigan, B. Imperiali, *Tetrahedron* **2007**, *63*, 6185.
 [17] P. E. Dawson, T. W. Muir, I. Clark-Lewis, S. B. Kent, *Science* **1994**, *266*, 776.
 [18] K. M. Trybus, *Methods* **2000**, *22*, 327.
 [19] J. R. Sellers, *Curr. Protoc. Cell Biol.* **2001**, *Chapter 13*, Unit 13.2.
 [20] M. Ikebe, D. J. Hartshorne, M. Elzinga, *J. Biol. Chem.* **1986**, *261*, 36.
 [21] a) H. Kamisoyama, Y. Araki, M. Ikebe, *Biochemistry* **1994**, *33*, 840; b) A. R. Bresnick, V. L. Wolff-Long, O. Baumann, T. D. Pollard, *Biochemistry* **1995**, *34*, 12576.
 [22] P. A. Ellison, J. R. Sellers, C. R. Cremo, *J. Biol. Chem.* **2000**, *275*, 15142.
 [23] G. Cuda, E. Pate, R. Cooke, J. R. Sellers, *Biophys. J.* **1997**, *72*, 1767.

Entry for the Table of Contents (Please choose one layout)


Layout 2:

Caged Proteins

Brenda N. Goguen, Brenton D.
Hoffman, James R. Sellers, Martin A.
Schwartz, and Barbara Imperiali

_____ Page – Page

Light-Triggered Myosin Activation for
Probing Dynamic Cellular Processes



Shining light on myosin: Incorporation of a caging group onto the essential phosphoserine of myosin by protein semisynthesis enables light-triggered activation of the protein. Caging eliminates myosin activity, but exposure to 365 nm light restores function to native levels. Introduction of the caged protein into cells and irradiation releases the native phosphoprotein to facilitate studies of myosin with precise spatial and temporal resolution.

Supporting Information

Light-Triggered Myosin Activation for Probing Dynamic Cellular Processes

Brenda N. Goguen, Brenton D. Hoffman, James R. Sellers, Martin A. Schwartz, and Barbara Imperiali

Table of Contents

Supplementary Figures	S2
Supplementary Table 1	S2
Supplementary Figure 1.....	S3
Supplementary Figure 2.....	S4
Supplementary Figure 3.....	S5
Supplementary Figure 4.....	S5
Supplementary Figure 5.....	S6
Supplementary Figure 6.....	S6
Methods	S7
Abbreviations	S7
Materials	S7
Peptide Synthesis.....	S7
Peptide Thioester Synthesis.....	S8
Cloning	S8
mRLC Expression	S9
Isolation and Purification of GST-mRLC.....	S9
TEV Cleavage	S10
Native Chemical Ligation.....	S10
Purification of Semisynthetic mRLC	S10
MALDI Analysis	S10
Proteins for ATPase and Sliding Filament Assays	S10
Myosin and HMM Exchange	S11
HMM Phosphorylation by Myosin Light Chain Kinase.....	S11
Uncaging.....	S11
Western Blots	S11
ATPase Assays	S12
Sliding Filament Assays	S12
Cellular Experiments	S12
References	S13

Table S1. Characterization of Peptide Thioesters

Peptide Thioester	Sequence	Molecular Formula	Molecular Weight Calculated	$[MH_5]^{5+}$ Calculated	$[MH_5]^{5+}$ Found ^[a]	HPLC (t_R) ^[b]
Non-phosphorylated	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRATSNVFA-COSBn	C ₁₆₀ H ₂₆₁ N ₄₇ O ₅₂ S	3704.89	742.0	742.0	21.3
pSer19	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRAT pS NVFA-COSBn	C ₁₆₀ H ₂₆₂ N ₄₇ O ₅₅ PS	3784.86	758.0	758.0	21.0
pThr18	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRA pT SNVFA-COSBn	C ₁₆₀ H ₂₆₂ N ₄₇ O ₅₅ PS	3784.86	758.0	758.0	20.9
pThr18 pSer19	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRA pTpS NVFA-COSBn	C ₁₆₀ H ₂₆₃ N ₄₇ O ₅₈ P ₂ S	3864.83	774.0	774.0	20.6
Caged pSer19	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRAT cpS NVFA-COSBn	C ₁₆₈ H ₂₆₉ N ₄₈ O ₅₇ PS	3933.91	787.8	787.9	22.1
Caged Thiophospho-Ser19	Ac-DYKDDDDKSSKKA ^{TKT} TKKRPQRAT cp(S)S NVFA-COSBn	C ₁₆₈ H ₂₆₉ N ₄₈ O ₅₆ PS ₂	3949.89	791.0	791.1	22.6

[a] The data were collected by positive ion electrospray ionization mass spectrometry. [b] Retention times were obtained from reverse phase HPLC analytical runs (YMC C₁₈, ODS-A, 5 μ m, 4.6 \times 250 mm) using the following method: 5% acetonitrile in water with 0.1% TFA for 5 min, followed by a linear gradient of 5-95% acetonitrile in water with 0.1% TFA over 30 min at 1 mL min⁻¹.




Figure S1. Synthesis and Purification of Semisynthetic mRLC. Coomassie-stained 12% SDS PAGE gel of the mRLC semisynthesis showing GST-TEV-mRLC- His_6 after purification by glutathione resin (*lane 1*), the TEV cleavage of GST-TEV-mRLC- His_6 (*lane 2*), the crude native chemical ligation reaction (*lane 3*), the protein purified by Ni-NTA affinity chromatography (*lane 4*), and the final semisynthetic mRLC after FLAG-affinity purification (*lane 5*).




Figure S2. Exchange of semisynthetic mRLC into HMM and Myosin. a) 12% SDS PAGE gel of a representative HMM exchange showing unexchanged HMM (*lane 1*), caged semisynthetic mRLC (*lane 2*), HMM purified after the first exchange (*lane 3*), and HMM purified after the second exchange (*lane 4*). b) 12% SDS PAGE gel of a representative myosin exchange showing native myosin (*lane 1*), caged semisynthetic mRLC (*lane 2*), myosin after the first exchange (*lane 3*), and myosin after the second exchange (*lane 4*). For both HMM and myosin, two consecutive exchanges leads to over 95% incorporation of the semisynthetic mRLC. Due to the addition of the N- and C-terminal tags, the mobility of the semisynthetic mRLC, compared to the native mRLC, is reduced on the SDS PAGE gel.




Figure S3. Uncaging time course of caged pSer19 mRLC peptide. A solution of the caged pSer19-mRLC peptide acid (86 μ M) in 10 mM HEPES (pH 7.1), 5 mM DTT, and 0.8 μ M inosine was irradiated on a transilluminator (365 nm) for the indicated times in a quartz vessel (1 mm pathlength). The peptide species were quantified by analytical RP-HPLC monitored at 228 nm. The areas of the caged and uncaged peptide peaks relative to the area of the inosine peak were determined. The percent of each species relative to the initial amount of the caged peptide is plotted against the duration of irradiation.




Figure S4. Uncaging of Caged Phosphoserine19 and Caged Thiophosphoserine19 mRLC. Western blot probed with an antibody specific for the pSer19 mRLC showing the caged pSer19 (5) and caged thiophosphoserine19 (6) mRLCs with no irradiation (*lanes 1 and 3, respectively*) and after 90 s irradiation on a transilluminator (*lanes 2 and 4, respectively*).




Figure S5. Actin Filament Paths with the Caged Thiophosphoserine19 mRLC. Filament paths in the sliding filament assay with non-irradiated (-UV) and irradiated (+UV) myosin exchanged with caged thiophosphoserine19 mRLC (6).




Figure S6. Cellular Uncaging Assessed by pSer19 mRLC Antibody Staining. COS-7 cells were injected with a solution of 6 and Texas Red dextran, exposed to UV irradiation (2 min on a transilluminator) if indicated, fixed, permeabilized, and stained for pSer19 mRLC. The intensity of anti-pSer19 mRLC antibody staining in individual cells is plotted against the dextran fluorescence intensity, which corresponds to the amount of protein that was injected.

Materials and Methods

Abbreviations

ATP: adenosine triphosphate; BSA: bovine serum albumin; CIP: calf intestinal phosphatase; DCM: dichloromethane; DIPEA: *N,N*-diisopropylethylamine; DMF: *N,N*-dimethylformamide; DTT: dithiothreitol; EDTA: ethylenediaminetetraacetic acid; EGTA: glycol-bis(2-aminoethylether)-*N,N,N',N'*-tetraacetic acid; ESI-MS: electrospray ionization mass spectrometry; Fmoc: 9-fluorenylmethoxycarbonyl; GST: glutathione-S-transferase; HATU: *O*-(7-azabenzotriazole-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate; HBTU: *O*-benzotriazole-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate; HMM: heavy meromyosin; HOAt: 1-hydroxy-7-azabenzotriazole; HOBt: 1-hydroxy-benzotriazole; HPLC: high performance liquid chromatography; IPTG: isopropyl-1-thio- β -D-galactopyranoside; LB: Luria-Bertani; MALDI: matrix-assisted laser desorption ionization; MOPS: 3-(*N*-morpholino)propanesulfonic acid; MWCO: molecular weight cut off; NTA: nitrilotriacetic acid; PBS: phosphate-buffered saline; PyBOP: benzotriazole-1-yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate; SDS: sodium dodecyl sulfate; SDS PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBS: tris-buffered saline; TBST: tris-buffered saline with Tween-20; TFA: trifluoroacetic acid; TEV: tobacco etch virus; TIRF: total internal reflection fluorescence; TNBS: 2,4,6-trinitrobenzene sulfonic acid; Tris: tris(hydroxymethyl)aminomethane; TRITC: tetramethyl rhodamine isothiocyanate.

Materials

Unless otherwise noted, all reagents and solvents for peptide synthesis were obtained commercially from Sigma Aldrich and used without further purification. Anhydrous DCM was distilled from calcium hydride. NovaSyn TGT resin, Fmoc-amino acids, PyBOP, HATU, HOAt, HBTU, and HOBt were obtained from Novabiochem. BL-21 Codon Plus RP cells were obtained from Agilent Technologies, Protease Inhibitor Cocktail Set III was from Calbiochem, Glutathione Sepharose 4 Fast Flow was obtained from GE Healthcare, Ni-NTA affinity resin was from Qiagen, and anti-FLAG M2 agarose was obtained from Sigma Aldrich. Amicon Ultra centrifugal filter devices were obtained from Millipore, and Slide-A-Lyzer dialysis cassettes, goat anti-rabbit IgG + IgM (H+L) alkaline phosphatase 2° antibody, and 1-Step NBT/BCIP substrate for alkaline phosphatase were from Thermo Fisher Scientific. Rabbit anti-pSer19 mRLC antibodies for Western blots and cellular studies were obtained from GeneTex and GenScript, respectively. The Alexa Fluor 647 goat anti-rabbit antibody was purchased from Invitrogen. Chicken gizzards and rabbit skeletal muscle acetone powder were purchased from PelFreeze.

Peptide Synthesis

All peptides were synthesized by solid phase peptide synthesis either manually or on an Applied Biosystems 431A peptide synthesizer using Fmoc-protected amino acids. Each peptide synthesis was performed on a 0.04 mmol scale using a 0.2 mmol/g loading Fmoc-Ala-NovaSyn TGT resin, which installed alanine as the C-terminal residue for all peptides. The N-terminus was acetylated by reaction with acetic anhydride and pyridine in DMF (20 equivalents each).

The procedure for the manual synthesis follows. The resin (0.2 g, 0.04 mmol) was swelled in DCM (5 mL) for 5 min and then in DMF (5 mL) for 5 min. The resin was incubated (5 × 5 min) with 5 mL 20% 4-methylpiperidine in DMF and then washed with DMF (5 mL, 5 × 1 min). The next Fmoc-amino acid (0.24 mmol) dissolved in DMF (5 mL) with PyBOP (0.12 g, 0.24 mmol) was added. DIPEA (84 μ L, 0.48 mmol) was added, and the reaction was allowed to proceed for at least 45 min. The success of coupling was evaluated by a TNBS test, and if no beads turned red, the procedure was repeated using the next amino acid. Phosphopeptides were synthesized by employing commercially available Fmoc-Thr(PO(OBzl)-OH)-OH or Fmoc-Ser(PO(OBzl)-OH)-OH. The caged residues *N*- α -Fmoc-phospho(1-nitrophenylethyl-2-cyanoethyl)-L-serine and *N*- α -Fmoc-phosphorothioyl(1-nitrophenylethyl-2-cyanoethyl)-L-serine were synthesized according to Rothman, *et al.*^[1] and Aemissegger, *et al.*,^[2] respectively. These residues (0.08 mmol) were coupled with HATU (0.08 mmol), HOAt (0.08 mmol), and 2,4,6-collidine (0.10 mmol) to prevent β -elimination of the phosphotriester.

Peptides were prepared by automated solid phase peptide synthesis on an Applied Biosystems 431A synthesizer employing standard Fmoc-protected amino acids (4 equivalents relative to resin loading per coupling), HOBt and HBTU coupling reagents, and 4-methylpiperidine deprotections. Double couplings and acyl capping were performed. On the automated synthesizer, Ser1 and Ser2 were coupled as the corresponding pseudoproline dipeptide Fmoc-Ser(tBu)-Ser($\Psi^{\text{Me,Me}}$ pro)-OH, and Lys8 and Thr9 were incorporated using Fmoc-Lys(Boc)-Thr($\Psi^{\text{Me,Me}}$ pro)-OH. These pseudoproline dipeptides improved the yields and purities of the final peptides.

Peptide Thioester Synthesis

The N-terminal acyl-capped peptides (0.04 mmol) were cleaved from the TGT resin without side chain deprotection in 0.5% TFA in DCM for 2 h. The solution was evaporated to about 1 mL, and the peptide was precipitated with hexanes. The solution was rotovapped, and the peptide was dried in vacuo. The peptide was dissolved in freshly distilled DCM (12 mL) under argon. HATU (0.061 g, 0.16 mmol), HOAt (0.022 g, 0.16 mmol), benzyl mercaptan (94 μ L, 0.8 mmol), and 2,4,6-collidine (42 μ L, 0.32 mmol) were added, and the reaction was stirred at RT under argon for 4 h. Under these conditions, epimerization of the C-terminal alanine was minimized (to ~6% based on model studies). The reaction was then rotovapped to dryness, and the side chain protecting groups were removed in 10 mL of 95% TFA with 2.5% triisopropyl silane and 2.5% H₂O for 2 h. The TFA was evaporated, and the peptide was triturated with cold diethyl ether (40 mL, 3×). Peptides were purified by reverse phase HPLC with a Waters 600 automated control module on a YMC C₁₈ semi-preparative column (YMC-Pack ODS-A, 5 μ m, 20 × 250 mm) eluting with acetonitrile/water containing 0.1% TFA. For detection, a Waters 2487 dual wavelength absorbance detector was used to record at 228 nm and 280 nm. HPLC conditions were 5% acetonitrile in water with 0.1% TFA for 5 min followed by a linear gradient from 20% to 50% acetonitrile in water with 0.1% TFA over 45 min. Following lyophilization, correct mass was validated by ESI-MS on a Mariner electrospray mass spectrometer (PerSpective Biosystems) (Table S1). Purity was confirmed by analytical HPLC with a Beckman Ultrasphere C₁₈ reverse phase column (YMC ODS-A, 5 μ m, 4.6 × 250 mm).

Cloning

To generate the GST-mRLC protein fusion, the C-terminal portion of the mRLC was subcloned into the pGEX-4T-2 vector. The gene fragment encoding mRLC(25 – 171) was amplified by polymerase chain

reaction from a vector containing the full mRLC gene (GenBank Accession AK002885). The forward primer for PCR encoded a 5' *Eco*RI restriction site, followed by the TEV protease cleavage sequence (ENLYFQ) and the Met24Cys mutation, and the reverse primer was used to encode a C-terminal hexahistidine tag and 3' *Not*I restriction site. The sequences of the primers used for PCR are given below:

Forward primer:

5'-GCCGGAATTCGTGAGAACCTGTATTTCCAGTGCTTTGACCAGTCCCAGATC-3'

Reverse Primer:

5'-GCGAAAGACAAAGATGACCATCACCATCACCATCACTAGGCGGCCGCAAAAGG
GGGC-3'

The PCR amplicons were digested with *Eco*RI and *Not*I and ligated into the pGEX-4T-2 vector, which had been digested with *Eco*RI and *Not*I and treated with CIP. The ligated plasmid was transformed into DH5 α cells and grown on LB plates containing carbenicillin (50 μ g/mL).

mRLC Expression

The pGEX-mRLC plasmid was transformed into BL-21 Codon Plus RP cells, and the bacteria were grown on LB plates containing carbenicillin (50 μ g/mL) and chloramphenicol (30 μ g/mL). A single colony was selected and grown in LB media (5 mL) supplemented with carbenicillin (50 μ g/mL) and chloramphenicol (30 μ g/mL). This starter culture was used to inoculate a 1 L culture, which was incubated in a shaker at 225 rpm and 37 °C until an OD of ~0.6 at 600 nm was reached. The culture was cooled to 16 °C, and IPTG was added to 0.2 mM to induce protein expression. The culture was incubated overnight at 16 °C with shaking. The next day, the cells were harvested by centrifugation, and the cell pellets were stored at -80 °C until use.

Isolation and Purification of GST-mRLC

The cell pellet was thawed on ice and brought up in 40 mL of PBS (150 mM NaCl, 10 mM phosphate, pH 7.7) containing 1 mg/mL lysozyme, 1 mM DTT, and 1 μ L/mL Protease Inhibitor Cocktail Set III (100 μ M AEBSF, 80 nM Aprotinin, 5 μ M Bestatin, 1.5 μ M E-64, 2 μ M Leupeptin, 1 μ M Pepstatin A) for each liter of cells harvested. The cells were incubated on ice for 20 min and then sonicated on ice at 40% amplitude, 1 s on/1 s off for 45 s with a Sonics Vibra Cell sonicator. Cell debris were pelleted at 90,000 rpm for 1 h at 4 °C, and the lysate was passed through a 0.2 μ m filter. Glutathione Sepharose 4 Fast Flow (3 mL) was incubated with the cell lysate for 1.5 h at 4 °C. The resin was isolated with a brief centrifugation and washed with 120 mL PBS at 4 °C. The protein was eluted in four 3-mL fractions with buffer containing 10 mM reduced glutathione and 2 μ L/mL Protease Inhibitor Cocktail Set III in 50 mM Tris, pH 8.0. The protein was dialyzed in a 3,500 MWCO Slide-A-Lyzer dialysis cassette against PBS (3 \times 2 L). Protein concentration was determined through a BioRad assay with BSA as a standard.

TEV Cleavage

TEV cleavage was performed by incubating the GST-mRLC protein (1.6 mg/mL) with TEV protease in buffer containing 50 mM Tris, pH 8.0, 0.5 mM EDTA, and 5 mM β -mercaptoethanol for 3.5 h at 30 °C and then overnight at 4 °C. SDS PAGE confirmed complete proteolytic cleavage.

Native Chemical Ligation

The TEV-cleaved protein (NH₂-Cys-mRLC(25-171)-His₆) was concentrated to 14 mg/mL with an Amicon Ultra centrifugal filter device (MWCO 3,000). Native chemical ligation reactions were performed by combining the thioester peptide (1.2 mM) with the TEV-cleaved protein (0.8 mM) in a buffer containing 150 mM sodium 2-mercaptoethanesulfonate and 50 mM Tris (pH 8.0). The reactions were incubated for 18 h at RT. The mixture was then diluted to 2 mg/mL and dialyzed against PBS (3 × 2 L) in a Slide-A-Lyzer dialysis cassette (3,500 MWCO) to remove the thiol additives.

Purification of Semisynthetic mRLC

The ligation mixture was purified from excess peptide using Ni-NTA affinity chromatography. The crude ligation was incubated with 2 mL Ni-NTA resin in PBS (25 mM NaH₂PO₄, 25 mM Na₂HPO₄, 300 mM NaCl, pH 7.9) containing 5 mM imidazole. After 1 h at 4 °C, the resin was collected and washed with 120 mL PBS containing 5 mM imidazole. The protein was eluted with 12 mL of PBS containing 300 mM imidazole and dialyzed against TBS (50 mM Tris, 200 mM NaCl, pH 7.5, 3 × 2 L). The unligated protein was subsequently removed from the FLAG epitope-tagged ligation product using anti-FLAG M2 agarose. After incubating the protein with the resin in TBS for 1 h at 4 °C with gentle agitation, the resin was washed with 120 mL TBS. The protein was eluted in 1-mL fractions with 0.1 M glycine (pH 3.5) into 50 μ L of a solution of 1 M Tris (pH 7.8) and 0.8 M NaCl. The purification was repeated using the flow through to recover unbound protein. The pooled elutions from each purification were dialyzed into PBS.

MALDI Analysis

Mass analysis of the purified semisynthetic protein was obtained on a Voyager DESTR MALDI by the MIT Biopolymers Laboratory. For semisynthetic nonphosphorylated mRLC **1**: Expected [MH]⁺: 21479.8; Found [MH]⁺: 21482.4.

Proteins for ATPase and Sliding Filament Assays

Myosin was isolated from chicken gizzards according to Ikebe and Hartshorne.^[3] HMM was generated by myosin proteolysis according to Ikebe and Hartshorne using *Staphylococcus aureus* V8 protease, except that a GE Healthcare Superdex 200 HiLoad (16/60) size exclusion chromatography column was used for purification.^[4] Myosin light chain kinase was purified from chicken gizzards according to Ikebe, *et al.*,^[5] and actin was purified from rabbit skeletal muscle acetone powder following protocols by Pardee and Spudich.^[6]

Myosin and HMM Exchange

The semisynthetic mRLC was exchanged into smooth muscle myosin according to modified procedures by Sherwood, *et al.*^[7] and Ikebe, *et al.*^[8] Myosin (0.5 mg/mL) in exchange buffer (0.6 M NaCl, 20 mM sodium phosphate (pH 7.5), 10 mM DTT, 5 mM EDTA, 1 mM EGTA, and 5 mM ATP) was incubated for 30 min at 42 °C with about 5 molar equivalents of the semisynthetic mRLC. After cooling on ice, MgCl₂ was added to 20 mM. To remove excess light chains, the myosin was precipitated by overnight dialysis into 15 mM Tris (pH 7.5), 10 mM MgCl₂, and 1 mM DTT. The pellet was collected by centrifugation and washed with dialysis buffer. The pelleted protein was dissolved in the exchange buffer, and the protein was subjected to a second exchange to increase incorporation of the semisynthetic protein to at least 90%.

The conditions for exchange into HMM (0.5 M NaCl, 20 mM sodium phosphate (pH 7.5), 10 mM DTT, 5 mM EDTA, 1 mM EGTA, and 1 mM ATP) were modified from Ellison, *et al.*^[9] The HMM was incubated with a 5-fold excess of the semisynthetic mRLC at 42 °C for 30 min. After cooling on ice, MgCl₂ was added to 20 mM, and the excess light chains were purified from HMM through size exclusion chromatography on a GE Healthcare Superdex 200 (10/300 GL) column equilibrated in 30 mM Tris (pH 7.5), 300 mM NaCl, 1 mM MgCl₂, and 0.5 mM DTT. Fractions containing HMM were pooled and concentrated in a 50,000 MWCO centrifugal filter unit, and the exchange was repeated.

HMM Phosphorylation by Myosin Light Chain Kinase

HMM was phosphorylated through a modified protocol from Ellison, *et al.*^[9] HMM (0.5 mg/mL in 15 mM Tris (pH 7.4), 50 mM NaCl, 2.5 mM MgCl₂, and 3.5 mM CaCl₂) was incubated with ATP (1.4 mM), myosin light chain kinase (30 µg/mL), and calmodulin (4 µg/mL) for 1 h at RT and then overnight at 4 °C.

Uncaging

Myosin or HMM exchanged with the caged semisynthetic protein in the appropriate assay buffer supplemented with 5 mM DTT was irradiated in a quartz vessel with a 1 mm pathlength on a UVP High Performance Ultraviolet Transilluminator with light centered at 365 nm (7330 µW/cm²) for 90 s.

Western Blots

Standard SDS PAGE on a 12% polyacrylamide gel was performed, and the proteins were transferred to a nitrocellulose membrane at 100 V for 1 h. The blot was blocked with 5% BSA in TBST (TBS with 0.05% Tween 20) overnight at 4 °C and then incubated with a rabbit anti-pSer19 mRLC antibody (1/1000 dilution) in 3% BSA in TBST for 2 h at RT. The blot was washed in TBST (5 × 5 min) and incubated with a goat anti-rabbit IgG + IgM (H+L) alkaline phosphatase 2° antibody in TBST (1/5000 dilution) for 1 h at RT. The blot was then washed with TBST (3 × 5 min) and TBS (1 × 5 min) and developed with 1-Step NBT/BCIP substrate for alkaline phosphatase.

ATPase Assays

The actin-activated ATPase activity of HMM was determined by measuring the inorganic phosphate released over 30 min.^[10] Assay conditions were modified from Ikebe and Hartshorne.^[4] HMM (0.1-0.2 mg/mL) in 30 mM Tris (pH 7.5), 2.5 mM MgCl₂, 20 mM KCl, 0.1 mM EGTA, and 1 mM DTT was incubated at 25 °C with actin (24 μM) in a final volume of 150 μL. All protein used in the assay was dialyzed into the assay buffer prior to the assay. The assay was initiated by the addition of ATP to 1 mM. For each time point, 30 μL of the myosin solution was added to 30 μL of the stop solution (60 mM EDTA (pH 6.5) with 6.6% SDS). To quantify the amount of inorganic phosphate present in each sample, 120 μL color developing solution (0.5% ammonium molybdate in 1 N H₂SO₄ with 18 mM ferrous sulfate) was added. After incubating the samples at RT for 20 min, the absorbance of the sample at 700 nm was measured. The rate of phosphate release was calculated based on a phosphate standard curve. Enzymatic activity (s⁻¹) was calculated using a molecular weight of 334,000 for HMM.

Sliding Filament Assays

Sliding filament assays were performed according to Sellers.^[11] To improve the quality of the actin filament movement, prior to each assay, myosin at 1 mg/mL in 0.5 M KCl, 10 mM MOPS (pH 7.0), 0.1 mM EGTA, 5 mM MgCl₂, 2 mM ATP, and 6 μM actin was centrifuged at 480,000 × g for 7 min to remove myosin containing heads that bind actin but that do not hydrolyze ATP. The supernatant was added at a concentration of about 0.2 mg/mL to a flow chamber constructed from a nitrocellulose-coated coverslip and microscope slide. The flow chamber was then blocked with 3 volumes BSA (1 mg/mL) in 0.5 M KCl, 10 mM MOPS (pH 7.0), and 0.1 mM EGTA and then washed with 3 volumes of motility buffer (20 mM MOPS (pH 7.4), 50 mM KCl, 4 mM MgCl₂, and 0.1 mM EGTA). Sheared actin (5 μM) with 1 mM ATP in motility buffer was added to block myosin heads that do not hydrolyze ATP, and the flow cell was washed with 3 volumes of motility buffer. TRITC-phalloidin labeled F-actin (20 nM) in motility buffer was added, and the assay was started by the addition of assay buffer (motility buffer containing 1 mM ATP, 20 mM DTT, 0.7% methylcellulose, 2.5 mg/mL glucose, 0.1 mg/mL glucose oxidase, and 20 μg/mL catalase). For native myosin phosphorylated by myosin light chain kinase, the wash containing sheared actin also contained 2 μg/mL myosin light chain kinase, 0.2 mM calmodulin, and 0.2 mM CaCl₂. Analysis of the uncaged myosin was performed by irradiating the protein in the presence of 5 mM DTT prior to its addition to the flow chamber. While movement was observed if the flow chamber itself was irradiated, the quality of the images was compromised due to photobleaching of the TRITC-labeled actin during irradiation. Filament movement was observed with a 100x objective on an Olympus IX50 microscope equipped with a Videoscope ICCD intensified CCD camera and recorded on a Panasonic VHS recorder. Data was quantified using the Cell Tracker software from Motion Analysis and was analyzed according to Homsher, *et al.*^[12]

Cellular Experiments

COS-7 cells were cultured in Dulbecco Modified Eagle's Media supplemented with 10% fetal bovine serum at 37 °C in a humidified environment with 5% CO₂. For injection and imaging experiments, cells were transferred to custom-made, glass-bottom pertri dishes comprised of a No. 1.5 coverslip coated with 2 μg/mL fibronectin overnight at 4 °C. Microinjection needles were pulled from borosilicate glass micropipettes (inner diameter = 0.78 mm, outer diameter = 1.0 mm, with filament) using a Model PC 84 Sachs-Flaming Micropipette puller. Micropipette tip size was estimated to be ~0.5 μm.^[13] To prevent the

needle from clogging, myosin at ~2.5 mg/mL in sterile PBS supplemented with 295 mM KCl, 0.5 mM DTT, and 1 mg/mL Texas Red-conjugated 10,000 MW lysine-fixable dextran was centrifuged at 75,000 × g for 30 min at 4 °C. The supernatant was then back-loaded into the micropipettes and injected into cells at a pressure of 0.8-1.8 psi using a Narishige IM 300 Microinjector mounted on a Nikon Diaphot microscope. To prevent inadvertent uncaging during injection, a glass UV filter (blocking < 400 nm light) and a red additive dichroic color filter (passing > 600 nm light) were placed in the transillumination beam path, and cells were never exposed to arc lamp illumination. For injection, cells were maintained in culture media supplemented with 150 mM KCl to enhance myosin solubility and to prevent the needle from clogging. Post-injection, cells were returned to culture media and allowed to recover for 1-4 h.

Uncaging was accomplished by exposing cells to the emission of a Stratagene 2020E transilluminator for 2 min. Cells were allowed to recover for 20 min. The cells were then fixed with 2% formaldehyde and permeabilized with 0.05% saponin. Cells were blocked with a solution of 2% BSA and 0.05% saponin and incubated with a rabbit phospho-specific mRLC antibody diluted 1:400 in blocking buffer. Cells were then blocked and stained with Alexa Fluor 647 goat anti-rabbit antibody diluted 1:400 in blocking buffer. PBS was used as the media during imaging experiments. Cells were imaged on a Nikon TE 300 Microscope equipped with a 100x TIRF lens and a HQ2 Cool Snap Camera. Texas Red-conjugated dextran and Alexa Fluor 647 were imaged through standard filter sets with 500 ms exposures.

References

- [1] D. M. Rothman, M. E. Vazquez, E. M. Vogel, B. Imperiali, *J. Org. Chem.* **2003**, *68*, 6795.
- [2] A. Aemissegger, C. N. Carrigan, B. Imperiali, *Tetrahedron* **2007**, *63*, 6185.
- [3] M. Ikebe, D. J. Hartshorne, *J. Biol. Chem.* **1985**, *260*, 13146.
- [4] M. Ikebe, D. J. Hartshorne, *Biochemistry* **1985**, *24*, 2380.
- [5] M. Ikebe, M. Stepinska, B. E. Kemp, A. R. Means, D. J. Hartshorne, *J. Biol. Chem.* **1987**, *262*, 13828.
- [6] J. D. Pardee, J. A. Spudich, *Methods Enzymol.* **1982**, *85 Pt B*, 164.
- [7] J. J. Sherwood, G. S. Waller, D. M. Warshaw, S. Lowey, *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 10973.
- [8] M. Ikebe, R. Ikebe, H. Kamisoyama, S. Reardon, J. P. Schwonek, C. R. Sanders II, M. Matsuura, *J. Biol. Chem.* **1994**, *269*, 28173.
- [9] P. A. Ellison, J. R. Sellers, C. R. Cremona, *J. Biol. Chem.* **2000**, *275*, 15142.
- [10] K. M. Trybus, *Methods* **2000**, *22*, 327.
- [11] J. R. Sellers, *Curr. Protoc. Cell Biol.* **2001**, *Chapter 13*, Unit 13.2.
- [12] E. Homsher, F. Wang, J. R. Sellers, *Am. J. Physiol.* **1992**, *262*, C714.
- [13] N. Hagag, M. Viola, B. Lane, J. K. Randolph, *Biotechniques* **1990**, *9*, 401.